"Last February, the World Health Organization declared a public health emergency over concerns about very serious birth defects in Brazil and their possible link to Zika virus. But even before then, concerns about the unprecedented spread of Zika "...
Immunization with Typhim Vi vaccine should occur at least two weeks prior to expected exposure to S typhi.
Typhim Vi vaccine is not indicated for routine immunization of individuals in the United States (US). 14
Selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with S typhi. 14
Typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as Africa, Asia, and Central and South America where there is a recognized risk of exposure to S typhi. Current CDC advisories should be consulted with regard to specific locales. Vaccination is particularly recommended for travelers who will have prolonged exposure to potentially contaminated food and water. However, even travelers who have been vaccinated should use caution in selecting food and water. 15
There is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disaster or in persons attending rural summer camps.14
An optimal reimmunization schedule has not been established. Reimmunization every two years under conditions of repeated or continued exposure to the S typhi organism is recommended at this time.
For recommended primary immunization and reimmunization see DOSAGE AND ADMINISTRATION section.
Typhim Vi vaccine should not be used to treat a patient with typhoid fever or a chronic typhoid carrier.
DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The syringe or vial and its packaging should also be inspected prior to use for evidence of leakage, premature activation of the plunger, or a faulty tip seal. If any of these conditions exists, the vaccine should not be administered.
For intramuscular use only. Do NOT inject intravenously.
The immunizing dose for adults and children is a single injection of 0.5 mL. The dose for adults is typically given intramuscularly in the deltoid, and the dose for children is given IM either in the deltoid or the anterolateral thigh. The vaccine should not be injected into the gluteal area or areas where there may be a nerve trunk.
A reimmunizing dose is 0.5 mL. Reimmunization consisting of a single dose for US travelers every two years under conditions of repeated or continued exposure to the S typhi organism is recommended at this time.14
The syringe is intended for single use only, must not be reused, and must be disposed of properly and promptly following its use.
The skin at the site of injection first should be cleansed and disinfected. Tear off upper seal of vial cap. Cleanse top of rubber stopper of the vial with a suitable antiseptic and wipe away all excess antiseptic before withdrawing vaccine.
Syringe, without needle, 0.5 mL, NDC 49281-790-88. Packaged as NDC 49281-790-51. Vial, 20 Dose, NDC 49281-790-38. Packaged as NDC 49281-790-20.
Store at 2. to 8.C (35. to 46.F). DO NOT FREEZE.
10 Unpublished data available from Sanofi Pasteur Inc., compiled 1991
11 Unpublished data available from Sanofi Pasteur SA
13 Keitel WA, et al. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccines 12: 195-199, 1994
14 Recommendations of the Immunization Practices Advisory Committee (ACIP). Typhoid Immunization. MMWR 43: No. RR-14, 1994
15 CDC. Health Information for International Travel 2001-2002. Atlanta: US Department of Health and Human Services, Public Health Service, 2001
Manufactured by: Sanofi Pasteur SA, Lyon, France, US Govt License #1724. Distributed by: Sanofi Pasteur Inc. Swiftwater PA 18370 USAThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/1/2015
Additional Typhim Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.